ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience.
Age Factors
Aged
Angiogenesis Inhibitors
/ administration & dosage
Bevacizumab
/ administration & dosage
Carcinoma, Ovarian Epithelial
/ drug therapy
Case-Control Studies
Databases, Factual
Female
Humans
Maintenance Chemotherapy
/ adverse effects
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Ovarian Neoplasms
/ drug therapy
Progression-Free Survival
Retrospective Studies
Bevacizumab
Chemotherapy
Elderly
Ovarian Cancer
Toxicity
Journal
Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
28
03
2019
revised:
01
07
2019
accepted:
08
07
2019
pubmed:
4
12
2019
medline:
31
3
2021
entrez:
3
12
2019
Statut:
ppublish
Résumé
Bevacizumab maintenance following platinum-based chemotherapy is an effective treatment for epithelial ovarian cancer (EOC), both in primary and recurrent disease. Our aim was to identify criteria to select elderly patients who can safely benefit from bevacizumab addition. This is a case-control study on patients with primary or recurrent EOC who received platinum-based chemotherapy plus bevacizumab, between January 2015 and December 2016. Patient characteristics, treatment details and adverse events were reviewed and analyzed in 2 settings: younger (<65 years, group 1) and elderly (≥65 years, group 2). A binary logistic model was applied to correlate clinical variables and severe (grade ≥3) toxicity risk. Overall, 283 patients with EOC were included, with 72 (25.4%) older patients compared with 211 (74.6%) younger women. Bevacizumab had been administered to 234 patients (82.7%) as first-line treatment and in 49 (17.3%) with recurrent disease. At diagnosis, elderly patients presented with at least one comorbidity and were taking at least 1 medication in 84.7% and 80.6% of the cases respectively, compared with correspondingly 47.4% and 37.4% in group 1 (p<0.001). Nonetheless, the occurrence of serious (grade ≥3) adverse events did not increase among the older group. Creatinine serum levels >1.1 g/dL, estimated glomerular filtration rate (eGFR) ≤60 mL/min, ≥3 comorbidities were independently associated with a higher severe toxicity. Elderly patients with EOC can safely be treated with bevacizumab; factors other than age, as higher creatinine serum levels, eGFR and number of comorbidities should be considered to better estimate bevacizumab-related toxicity risk.
Identifiants
pubmed: 31788996
pii: 31.e6
doi: 10.3802/jgo.2020.31.e6
pmc: PMC6918885
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e6Informations de copyright
Copyright © 2020. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
J Clin Oncol. 2009 Jun 10;27(17):2758-65
pubmed: 19403886
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
CA Cancer J Clin. 2010 Mar-Apr;60(2):120-32
pubmed: 20173172
J Am Geriatr Soc. 2006 Jun;54(6):991-1001
pubmed: 16776798
Cochrane Database Syst Rev. 2017 Sep 12;9:CD006211
pubmed: 28898390
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
J Gynecol Oncol. 2019 Jan;30(1):e11
pubmed: 30479095
J Geriatr Oncol. 2016 Sep;7(5):346-53
pubmed: 27498305
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
JAMA. 2012 May 9;307(18):1941-51
pubmed: 22570462
Int J Gynecol Cancer. 2018 May;28(4):729-737
pubmed: 29498983
J Geriatr Oncol. 2017 Jan;8(1):44-49
pubmed: 27491499
Aging Dis. 2017 Oct 1;8(5):677-684
pubmed: 28966809
Ann Thorac Surg. 2008 Jul;86(1):1-3
pubmed: 18573388